Moderna Therapeutics
About
Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
- Cambridge,Massachusetts,United States
- 1001 - 5000
- http://www.modernatx.com
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $250M
- Industries
- Biotechnology,Genetics,Health Care,Medical,Pharmaceutical
- Founded date
- Jan 1, 2010
- Number Of Employee
- 1001 - 5000
- Operating Status
- Active
- Stock Symbol
- nasdaq:MRNA
- Legal Name
- Moderna, Inc.
- Also Known As
- Moderna
Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies inside patient cells.
Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology.
Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 12, 2022 | Post-IPO Equity | $250M | 1 |
MSD Capital
|
— | Detail |
| Jul 26, 2020 | Grant | $472M | 1 |
Biomedical Advanced Research and Development Authority (BARDA)
|
— | Detail |
| Apr 17, 2020 | Grant | $483M | 1 |
Biomedical Advanced Research and Development Authority (BARDA)
|
— | Detail |
| Dec 6, 2018 | IPO | $604M | — | — | — | Detail |
| May 3, 2018 | Series H | $125M | 1 |
Merck
|
— | Detail |
Investments
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Jan 25, 2022
Metagenomi
|
Series B | $175M | Artificial Intelligence | — |
|
Jan 14, 2014
|
Series Unknown | $20M | Biotechnology | Yes |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
MSD Capital
|
Yes | Post-IPO Equity |
|
Biomedical Advanced Research and Development Authority (BARDA)
|
Yes | Grant |
|
Merck
|
Yes | Series H |
AstraZeneca
|
Yes | Series F |
DARPA
|
Yes | Grant |
Abu Dhabi Investment Authority
|
— | Series G |
Alexandria Venture Investments
|
— | Series G |
ArrowMark Partners
|
— | Series G |
BB Biotech Ventures
|
— | Series G |
EDBI
|
— | Series G |
Employee Profiles
